Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be...
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be...
Prestigious Hacettepe University Hospital Expands Radiation Oncology Department to Offer the Latest Robotic Advance in Brain Tumor TreatmentsSAN CARLOS, Calif.--(BUSINESS...
AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as...
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed...
STOCKHOLM, SE / ACCESSWIRE / September 26, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a...
Chronic spinal cord injury cohort results expected in mid-2024 Subacute spinal cord injury cohort results expected in late 2024/early 2025Vancouver,...
Further Supports TTX-MC138 Application in Brain CancerBOSTON, Sept. 25, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA...
BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
Brain Canada’s Future Leaders in Canadian Brain Research program to support 28 early-career researchers this year The 2022 Future Leaders...
New Approach to Measuring Impact of Counselling to Deliver Next Generation Care to Mental Health Sufferers in North AmericaVancouver, British...
Advanced technology enhances Intracept Procedure training for the treatment of vertebrogenic painCHICAGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- IPSIS Annual...
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1...
Replay announces partnership between product company Syena and JURA Bio to advance T cell receptor NK therapies in cancer Collaboration...
CARMEL, Ind., Sept. 21, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company...
Company’s First-Ever ANPT Booth Sponsorship Enables Specialists to Learn More about this Breakthrough Technology on Eve of National Physical Therapy...
JACKSON CENTER, PA / ACCESSWIRE / September 20, 2023 / Halberd Corporation (OTC PINK:HALB) and Athena GTX, Inc, of Johnston,...
BOSTON and ATLANTA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical...
STOCKHOLM, SE / ACCESSWIRE / September 20, 2023 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR),...
Toronto, Ontario--(Newsfile Corp. - September 19, 2023) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light...
EU Patent #19846183.2 - A NOVEL BOTANICAL AND TETRAHYDROCANNABINOL ("THC") FORMULATION FOR THE REDUCTION OF CANNABIS-INDUCED NEGATIVE NEUROPSYCHIATRIC SIDE-EFFECTSWe believe...